Target (CBDY) Return on Capital Employed (2014 - 2026)
Target (CBDY) reported Return on Capital Employed of 8.9% for Q1 2026, up 3110.0% year-over-year from 0.28% in Q1 2025, and up 188.82% quarter-over-quarter from 3.08% in Q4 2025.
Target (CBDY) Return on Capital Employed (2014 - 2026) Analysis & Trends
Target (CBDY) has 13 years of Return on Capital Employed data on file, last reported at 8.9% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 8.9%, up 3110.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 8.9% (up 3110.0% YoY), and the FY2025 annual result was 3.41%, up 2625.0% from the prior year.
- Return on Capital Employed improved to 8.9% in Q1 2026 per CBDY's latest filing, from 3.08% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 19.91% in Q2 2023 and troughed at 69.32% in Q3 2023.
- A 5-year average of 8.96% and a median of 3.96% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed plunged 7151 bps in 2023, then soared 5447 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 2.19% in 2022, then jumped by 144 bps to 5.36% in 2023, then tumbled by 478 bps to 20.24% in 2024, then jumped by 115 bps to 3.08% in 2025, then surged by 189 bps to 8.9% in 2026.
- Business Quant data shows CBDY's Return on Capital Employed at 8.9% in Q1 2026, 3.08% in Q4 2025, and 5.94% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 8.52% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 27.58% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 21.43% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 20.04% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 7.34% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 6.92% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -1.92% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 14.85% |
| 10 | Target | - | - | 191,787.00 | 8.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.90% |
| Dec 31, 2025 | 3.08% |
| Sep 30, 2025 | -5.94% |
| Jun 30, 2025 | -11.83% |
| Mar 31, 2025 | -22.20% |
| Dec 31, 2024 | -20.24% |
| Sep 30, 2024 | -14.85% |
| Jun 30, 2024 | -18.06% |
| Mar 31, 2024 | -0.41% |
| Dec 31, 2023 | 5.36% |
| Sep 30, 2023 | -69.32% |
| Jun 30, 2023 | 19.91% |
| Sep 30, 2022 | 2.19% |
| Jun 30, 2022 | -1.98% |
| Sep 30, 2021 | -12.70% |
| Jun 30, 2021 | -15.60% |
| Mar 31, 2021 | -16.92% |
| Dec 31, 2020 | -15.23% |
| Sep 30, 2020 | -18.28% |
| Jun 30, 2020 | -23.98% |